The present disclosure generally relates to compositions and techniques for treatment of vulvar and vaginal atrophy (VVA). In some embodiments, a composition comprising tamoxifen and/or pharmaceutically acceptable salts thereof. The composition may be applied intravaginally to a vagina of a subject. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., melatonin, a melatonin receptor agonist, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
The present disclosure generally relates to compositions and techniques for treatment of dysmenorrhea using intravaginal delivery. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 800,000 cP. The composition may also contain an active ingredient for treatment of dysmenorrhea (e.g., primary dysmenorrhea), e.g., diclofenac, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
The present disclosure generally relates to compositions and techniques for treatment of female sexual dysfunction (FSD), including female sexual arousal disorder (FSAD). In some embodiments, a composition such as a cream may be applied to the genital of a subject. The composition may also contain an active ingredient for treatment of FSD and/or FSAD, e.g., sildenafil, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for using such compositions, kits including such compositions, or the like.
The present invention is in the field of intravaginal rings, in particular segmented, ethylene-vinyl acetate (EVA) intravaginal rings, and their use treating, ameliorating, or preventing, vasomotor symptoms in perimenopause and/or menopausal women and for treating, ameliorating, or preventing vulvar and vaginal atrophy (VVA).
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the field of women's health; pharmaceutical preparations for treating dysmenorrhea, pelvic pain, sexual pain, and symptoms of endometriosis and menopause affecting sex; pharmaceutical preparations, namely, analgesic gels for vaginal use; pharmaceutical preparations, namely, selective estrogen receptor modulator suppositories for vaginal use; intravaginal drug delivery device for the continuous release of pharmaceutical preparations, sold filled with hormones; hormone replacement therapy preparations; hormones; vaginal preparations, namely, vaginal melatonin
The present disclosure relates to a pharmaceutical composition containing a poloxamer, a stabilization polymer, and Lactobacillus, as well as methods of making and using, and kits containing the composition.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary supplements; Vitamins; Probiotic preparations; Vaginal preparations and suppositories for balancing vaginal microbiome, restoring vaginal pH, support vaginal immune response, and enhance vaginal health; all of the foregoing featuring limosilactobacillus fermentum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary supplements; Vitamins; Probiotic preparations; Vaginal preparations and suppositories for balancing vaginal microbiome, restoring vaginal pH, support vaginal immune response, and enhance vaginal health; all of the foregoing featuring lacticaseibacillus rhamnosus
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating, preventing, and managing pain; Pharmaceutical preparations for treating dysmenorrhea, pelvic pain, sexual pain, endometriosis and symptoms of menopause affecting sex; Analgesics; Vaginal pharmaceutical preparations and suppositories for treatment of pain, release of selective estrogen receptor modulators, and vaginal melatonin; Intravaginal drug delivery device sold filled with hormones for the continuous release of hormones; Hormones; Hormone replacement therapy pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting women's health, sexual health, and reproductive health; Pharmaceutical preparations for use in the fields of women's health, reproductive health, and sexual health; Vaginal preparations and suppositories for use in the fields of women's health, reproductive health, and sexual health; Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting the vagina; Analgesics; Anti-infectives; Hormones; Hormone replacement therapy preparations; Vaginal pharmaceutical preparations; Vaginal suppositories; Vaginal nutritional supplements; Medicated topical creams for preventing, treating, managing diseases, disorders, and conditions affecting women's health, sexual health, and reproductive health; Dietary supplements; Vitamins; Probiotic nutritional supplements; Drug delivery agents, in the form of dissolvable compounds that facilitate the delivery of pharmaceutical preparations; Contraceptive pharmaceutical preparations Medical apparatus for use in women’s reproductive health and women’s sexual health; Contraceptive apparatus Research and development of medical preparations, medical products, and medical devices in the field of women’s health, reproductive health, and sexual health; Providing medical scientific research information in the fields of women’s health, reproductive health, and sexual health
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting women's health, sexual health, and reproductive health; Pharmaceutical preparations for use in the fields of women's health, reproductive health, and sexual health; Vaginal preparations and suppositories for use in the fields of women's health, reproductive health, and sexual health; Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting the vagina; Analgesics; Anti-infectives; Hormones; Hormone replacement therapy preparations; Vaginal pharmaceutical preparations; Vaginal suppositories; Vaginal nutritional supplements; Medicated topical creams for preventing, treating, managing diseases, disorders, and conditions affecting women's health, sexual health, and reproductive health; Dietary supplements; Vitamins; Probiotic nutritional supplements; Drug delivery agents, in the form of dissolvable compounds that facilitate the delivery of pharmaceutical preparations; Contraceptive pharmaceutical preparations Medical apparatus for use in women’s reproductive health and women’s sexual health; Contraceptive apparatus Research and development of medical preparations, medical products, and medical devices in the field of women’s health, reproductive health, and sexual health; Providing medical scientific research information in the fields of women’s health, reproductive health, and sexual health
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for contraception, menopause, pelvic pain, fertility, and infections in the fields of women's health, reproductive health, and sexual health; Pharmaceutical preparations for treating, managing, and preventing conditions, disease, and disorders affecting women's health, reproductive health, and sexual health; Vaginal preparations and suppositories, namely, anti-infectives, probiotics, contraceptives, hormones, hormone alternatives, hormone modulators analgesics, and aphrodisiacs for use in the fields of women's health, reproductive health, and sexual health; Pharmaceutical preparations for preventing, treating, managing diseases, disorders, and conditions affecting the vagina; Analgesics; Anti-infectives; Hormones; Hormone replacement therapy preparations; Vaginal preparations for preventing, treating, managing diseases, disorders, and conditions affecting the female reproductive system; Vaginal suppositories for preventing, treating, managing diseases, disorders, and conditions affecting the female reproductive system; Vaginal supplements for balancing vaginal microbiome and pH and promoting vaginal health; Medicated skin creams; medicated vaginal creams; Dietary supplements; Vitamins; Probiotic preparations for medical use; Drug delivery agents in the form of dissolvable compounds that facilitate the delivery of pharmaceutical preparations; Drug delivery devices sold filled with pharmaceutical preparations for treating, managing, and preventing conditions, disease, and disorders affecting women's health, reproductive health, and sexual health; Contraceptive preparations Medical apparatus for use in treating, managing, and preventing conditions, disease, and disorders affecting women's health, reproductive health, and sexual health; Contraceptive apparatus Research and development of medical preparations, medical products, and medical devices in the field of women’s health, reproductive health, and sexual health; Providing medical scientific research information in the fields of women’s health, reproductive health, and sexual health
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of topical cream that facilitate the delivery of pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the field of women's health, namely, for managing and supporting fertility, fertilization, conception, pregnancy, and complications related to all of the aforementioned; intravaginal drug delivery device for the continuous release of pharmaceutical preparations, sold filled with hormones for supporting in-vitro fertilization and regulating pre-term birth; hormones; hormones for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for treating dysmenorrhea, pelvic pain, sexual pain, and symptoms of endometriosis and menopause affecting sex; pharmaceutical preparations, namely, analgesic gels for vaginal use; pharmaceutical preparations, namely, selective estrogen receptor modulator suppositories for vaginal use; intravaginal drug delivery device for the continuous release of pharmaceutical preparations, sold filled with hormones; hormone replacement therapy preparations; hormones; vaginal preparations, namely, vaginal melatonin
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaginal suppositories being pharmaceutical preparations for promoting healthy microbiome; vaginal preparations, namely, probiotic compositions in the form of vaginal suppositories
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the field of women's health, namely, for treating, managing, and preventing conditions, diseaes, and disorders affecting the female reproductive system; Pharmaceutical preparations for treatment of female sexual arousal disorder, sexual pain, pelvic pain, dysmenorrhea, and symptoms of menopause and endometriosis affecting sex; Analgesic creams for vaginal and topical genital use; Creams for vaginal and topical genital use to increase blood flow through vasodilation
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the field of women's health, namely, for the management, treatment, and prevention of diseases, disorders, and conditions affecting female reproductive systems; pharmaceutical preparations for the treatment of vaginal infections; anti-infectives
21.
COMPOSITIONS AND METHODS FOR TREATING VULVAR AND VAGINAL ATROPHY (VVA)
The present disclosure generally relates to compositions and techniques for treatment of vulvar and vaginal atrophy (VVA). In some embodiments, a composition comprising tamoxifen and/or pharmaceutically acceptable salts thereof. The composition may be applied intravaginally to a vagina of a subject. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
24.
COMPOSITIONS AND METHODS OF TREATING FEMALE SEXUAL DYSFUNCTION AND FEMALE SEXUAL AROUSAL DISORDER
The present disclosure generally relates to compositions and techniques for treatment of female sexual dysfunction (FSD), including female sexual arousal disorder (FSAD). In some embodiments, a composition such as a cream may be applied to the genital of a subject. The composition may also contain an active ingredient for treatment of FSD and/or FSAD, e.g., sildenafil, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for using such compositions, kits including such compositions, or the like.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
25.
COMPOSITIONS AND METHODS FOR TREATING DYSMENORRHEA
The present disclosure generally relates to compositions and techniques for treatment of dysmenorrhea using intravaginal delivery. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 800,000 cP. The composition may also contain an active ingredient for treatment of dysmenorrhea (e.g., primary dysmenorrhea), e.g., diclofenac, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61F 6/06 - Contraceptive devicesPessariesApplicators therefor for use by females
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
26.
COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., hydroxychloroquine, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61F 6/06 - Contraceptive devicesPessariesApplicators therefor for use by females
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., melatonin, a melatonin receptor agonist, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A drug delivery device for use in the treatment of one or more symptoms of menopause in a subject, comprising intravaginally inserting the implantable drug delivery device to the subject, wherein the implantable drug delivery device comprises an estrogen and a progestin, and further wherein the implantable drug delivery device provides a baseline-adjusted steady state plasma estrogen concentration between about 15 pg/mL and about 50 pg/mL in the subject.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present disclosure generally relates to compositions and techniques for vaginal insertion. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. The composition may also contain an active ingredient, e.g., dinoprostone, diclofenac, and/or salts thereof. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. This may, for example, allow the composition to release the active ingredient over a relatively long period of time to the vagina. In some embodiments, such compositions may be prepared by removing air from the composition to increase its viscosity or cause the composition to form a gel, etc. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
32.
SYSTEMS AND METHODS FOR TREATMENT OF BACTERIAL VAGINOSIS
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa·s.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 9/00 - Medicinal preparations characterised by special physical form
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa.s.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa.s.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
A composition, comprising a poloxamer, a stabilization polymer, and diclofenac as an active ingredient suitable for treating dysmenorrhea, wherein the composition has a viscosity at room temperature of at least 1.5 million cP.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A composition, comprising a poloxamer, a stabilization polymer, and diclofenac as an active ingredient suitable for treating dysmenorrhea, wherein the composition has a viscosity at room temperature of at least 1.5 million cP.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring devices that are resistant to distortion due to absorption of vaginal fluids. This allows the rings to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
Disclosed herein are intravaginal ring devices that are resistant to distortion due to absorption of vaginal fluids. This allows the rings to perform better over time as compared to other intravaginal rings made with copolymeric silicone.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Contraceptive preparations Medical products, namely, a polymer intra-vaginal ring with an incorporated mesh insert that is designed to reside in the vaginal fornix, essentially covering the external orifice of the cervix, and medical devices and contraceptive apparatuses for vaginal and intrauterine contraception
